ArteraAI vs Valar Labs (2026)
Both sell AI tests read from routine H&E slides through their own CLIA certified laboratories, Artera in prostate cancer and Valar mainly in bladder cancer. ArteraAI Prostate also holds FDA De Novo authorization (DEN240068) as software, while the tests Artera runs in its laboratory are laboratory developed tests it states are not FDA cleared. Valar's Vesta Bladder tests predict non response to BCG and give recurrence and progression risk in non muscle invasive bladder cancer; one of them received a Breakthrough Device Designation in May 2026, and a prostate test is also offered.
- Prostate cancer is the decision in front of you.
- You want a test with an FDA De Novo authorization and a place in the NCCN guidelines.
- Performance across patient groups matters: a peer reviewed analysis reported comparable results for African American and other men across five phase III trials.
- Your patients have non muscle invasive bladder cancer and BCG response is the question.
- You want evidence from multicenter bladder studies, published in the Journal of Urology and European Urology.
- You want a prostate biomarker validated on two randomized phase 3 trials alongside the bladder tests.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. ArteraAI and Valar Labs are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | ArteraAI | Valar Labs |
|---|---|---|
| Primary category | Digital Pathology AI | Digital Pathology AI |
| Founded | Not recorded | 2021 |
| Headquarters | Los Altos, California | Palo Alto, California, United States |
| Website | artera.ai | valarlabs.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Note on naming: this is Artera of Los Altos, California (artera.ai), developer of multimodal AI cancer tests. The two companies share a name and nothing else.
Source: AI Health Index, September 2026
Palo Alto precision oncology company whose Vesta tests predict treatment response and prognosis from routine H&E slides, using its Computational Histology AI platform trained on more than 500,000 pathologist annotations. The tests are performed in the company's own CLIA certified, CAP accredited laboratory rather than sold as cleared devices: Vesta Bladder BCGPredict predicts non-response to BCG and Vesta Bladder Risk Stratify gives recurrence and progression risk in non-muscle invasive bladder cancer, with a prostate test also offered.
Source: AI Health Index, September 2026
Questions buyers ask
How do ArteraAI and Valar Labs work with the EHR?
For ArteraAI, the FDA authorized software version (DEN240068) takes whole slide images from FDA cleared interoperable scanners, which is scanner interoperability rather than record integration.
Practices send existing specimens to Valar's laboratory and receive results in about three days, so there is no platform to deploy, and a clinician quoted on the product page describes its integration into the practice's workflow. Reach is extended through laboratory partnerships with urology practices. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How are ArteraAI and Valar Labs priced and sold?
In ArteraAI's case, the home page says the test is fully reimbursed for Medicare patients and that many commercial health plans provide coverage, with a billing page linked, and CMS coverage is in place with a payment rate effective January 2024.
For Valar Labs, the company runs a Financial Access Program for patients with financial need. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How do ArteraAI and Valar Labs handle patient data?
With ArteraAI, the company's HIPAA Notice of Privacy Practices, linked in the footer, sets out who receives protected health information and why, requires patient authorization for marketing or any disclosure amounting to a sale, and gates research disclosure behind approval by an institutional review or privacy board; patients can obtain an accounting of disclosures.
The Notice of Privacy Practices (effective 1 January 2025) says Valar may de-identify PHI by removing identifying features as the law determines, may use and disclose PHI for research where legally required protections are taken, and needs written authorization for marketing and any sale of PHI. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
What evidence is published for ArteraAI and Valar Labs?
For ArteraAI, the test is included in the NCCN Clinical Practice Guidelines for Prostate Cancer, which the company describes as the first and only AI test in them, with a Level 1B evidence rating under Simon criteria and a Category 2A recommendation.
With Valar Labs, the company says its bladder models were developed and validated in more than 1,000 patients. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both run their tests in their own CLIA laboratories, and both notices of privacy practices give patients a right to request amendment of their results. A Breakthrough Device Designation on a Valar test is a development status, not an authorization. Rewritten 28 Sep 2026 after both records were reviewed.